Why it matters
A federal discovery/distribution layer is emerging for trusted digital health products, with explicit expectations around clinical evidence, privacy, usability, AI disclosure, and interoperability.
Decision implication
Digital-health products should treat CMS ecosystem eligibility, identity, evidence, privacy, usability, interoperability, and AI disclosure as potential distribution requirements—not afterthoughts.
Who or what is affected
- CMS
- Medicare beneficiaries
- health app developers
- AI assistants
- digital health platforms
- ACCESS participants
Evidence and sources
E5 — official CMS source
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- New app categories
- approved apps
- evidence/vetting criteria
- beneficiary adoption
- ACCESS exemptions.